Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs

Structural equilibrium underlying ligand-dependent activation of β2-adrenoreceptor

(2020) Shunsuke Imai et al.   Nature Chemical Biology

Binding of clozapine to the GABAB receptor: clinical and structural insights

(2020) Pramod C. Nair et al.   MOLECULAR PSYCHIATRY

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

(2020) Kenneth S. Koblan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor Binding

(2020) Donald C. Goff   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS

(2020) Szilárd Páll et al.   JOURNAL OF CHEMICAL PHYSICS

Arginine-259 of UDP-glycosyltransferase 2B7 (UGT2B7) confers UDP-sugar selectivity

(2020) Pramod C. Nair et al.   MOLECULAR PHARMACOLOGY

Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?

(2020) Seetal Dodd et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders

(2020) Sherry Kit Wa Chan et al.   SCHIZOPHRENIA BULLETIN

SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION

(2019) Nina Dedic et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

SWISS-MODEL: homology modelling of protein structures and complexes

(2018) Andrew Waterhouse et al.   NUCLEIC ACIDS RESEARCH

Trace Amines and Their Receptors

(2018) Raul R. Gainetdinov et al.   PHARMACOLOGICAL REVIEWS

The Case for TAAR1 as a Modulator of Central Nervous System Function

(2018) Grazia Rutigliano et al.   Frontiers in Pharmacology

Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist

(2018) Wanchao Yin et al.   Cell Discovery

Ten-year follow up of patients with first-episode schizophrenia spectrum disorder from an early intervention service: Predictors of clinical remission and functional recovery

(2018) Sherry Kit Wa Chan et al.   SCHIZOPHRENIA RESEARCH

Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges

(2017) Mark D. Berry et al.   PHARMACOLOGY & THERAPEUTICS

Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists

(2016) Guido Galley et al.   ACS Medicinal Chemistry Letters

Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers

(2015) Anja Harmeier et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists

(2015) Grazia Chiellini et al.   JOURNAL OF MEDICINAL CHEMISTRY

TAAR1 Modulates Cortical Glutamate NMDA Receptor Function

(2015) Stefano Espinoza et al.   NEUROPSYCHOPHARMACOLOGY

10-year outcome study of an early intervention program for psychosis compared with standard care service

(2014) S. K. W. Chan et al.   PSYCHOLOGICAL MEDICINE

Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials

(2014) Paolo Fusar-Poli et al.   SCHIZOPHRENIA BULLETIN

Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012

(2012) Guido Galley et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Insights into the Structure and Pharmacology of the Human Trace Amine-Associated Receptor 1 (hTAAR1): Homology Modelling and Docking Studies

(2012) Elena Cichero et al.   Chemical Biology & Drug Design

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

(2012) S Miyamoto et al.   MOLECULAR PSYCHIATRY

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight

(2012) F G Revel et al.   MOLECULAR PSYCHIATRY

A Systematic Review and Meta-Analysis of Recovery in Schizophrenia

(2012) E. Jaaskelainen et al.   SCHIZOPHRENIA BULLETIN

Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor

(2011) S. Espinoza et al.   MOLECULAR PHARMACOLOGY

TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity

(2011) F. G. Revel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

(2011) Adrian Newman-Tancredi et al.   PSYCHOPHARMACOLOGY

Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): Discovery of EPPTB (RO5212773)

(2010) Henri Stalder et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Rethinking schizophrenia

(2010) Thomas R. Insel   NATURE

Schizophrenia

(2009) Jim van Os et al.   LANCET

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Akt/GSK3 Signaling in the Action of Psychotropic Drugs

(2008) Jean-Martin Beaulieu et al.   Annual Review of Pharmacology and Toxicology

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

(2008) J. McGrath et al.   EPIDEMIOLOGIC REVIEWS

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

(2008) S Leucht et al.   MOLECULAR PSYCHIATRY